These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 6794355)

  • 41. Cytogenetic studies in Philadelphia chromosome-negative myeloproliferative disorders, particularly polycythaemia rubra vera.
    Lawler SD
    Clin Haematol; 1980 Feb; 9(1):159-74. PubMed ID: 6768481
    [No Abstract]   [Full Text] [Related]  

  • 42. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
    Balduini CL; Bertolino G; Noris P; Ascari E
    Haematologica; 1992; 77(1):40-3. PubMed ID: 1398280
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
    Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Platelet unresponsiveness to collagen: involvement of glycoprotein Ia-IIa (alpha 2 beta 1 integrin) deficiency associated with a myeloproliferative disorder.
    Handa M; Watanabe K; Kawai Y; Kamata T; Koyama T; Nagai H; Ikeda Y
    Thromb Haemost; 1995 Mar; 73(3):521-8. PubMed ID: 7667837
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sideroblastic anaemia with reactive thrombocytosis versus myelodysplastic/myeloproliferative disease.
    Pérez Sánchez I; Pérez Corrala A; Menarguez Palanca J; Mayayo Crespo M; Escudero Soto A; Pintado Cros T
    Leuk Lymphoma; 2003 Mar; 44(3):557-9. PubMed ID: 12688334
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults.
    Shaw GR
    Br J Haematol; 2005 Oct; 131(2):180-4. PubMed ID: 16197447
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anagrelide: a new drug for treating thrombocytosis.
    Silverstein MN; Petitt RM; Solberg LA; Fleming JS; Knight RC; Schacter LP
    N Engl J Med; 1988 May; 318(20):1292-4. PubMed ID: 3362187
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of risk factors: the rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia.
    Schwarz J; Pytlík R; Doubek M; Brychtová Y; Dulícek P; Campr V; Kren L; Penka M
    Semin Thromb Hemost; 2006 Apr; 32(3):231-45. PubMed ID: 16673277
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
    Spivak JL
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):1-5. PubMed ID: 12682874
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
    Hall J; Foucar K
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Leg pain and platelet aggregates in thrombocythemic myeloproliferative disease.
    Salem HH; van der Weyden MB; Koutts J; Firkin BG
    JAMA; 1980 Sep; 244(10):1122-3. PubMed ID: 7411766
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vivo platelet release in myeloproliferative disorders.
    Ireland H; Lane DA; Wolff S; Foadi M
    Thromb Haemost; 1982 Aug; 48(1):41-5. PubMed ID: 6215739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Platelet large cell ratio in the differential diagnosis of abnormal platelet counts.
    Babu E; Basu D
    Indian J Pathol Microbiol; 2004 Apr; 47(2):202-5. PubMed ID: 16295468
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Alteration of platelet function in myeloproliferative disorder and its clinical significance].
    Ni HY; Deng CG; Ruan HF; Pam CF; Li HR; Gon DQ
    Hua Xi Yi Ke Da Xue Xue Bao; 1988 Sep; 19(3):312-6. PubMed ID: 3253181
    [No Abstract]   [Full Text] [Related]  

  • 55. Pseudohyperkalaemia is a common finding in myeloproliferative disorders that may lead to inappropriate management of patients.
    Ong YL; Deore R; El-Agnaf M
    Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e151-7. PubMed ID: 19016918
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of splenectomy on platelet morphometry and function.
    Wehmeier A; Scharf RE; Schneider W
    Klin Wochenschr; 1990 Sep; 68(17):847-52. PubMed ID: 2214608
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transient thrombocytosis with megathrombocytes in a case of acute myeloblastic leukemia.
    Kotru M; Batra M; Gomber S; Rusia U
    Indian J Pathol Microbiol; 2009; 52(1):113-4. PubMed ID: 19136802
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Postsplenectomy thrombocythemia: an unmasked myeloproliferative disorder.
    Jamshidi K; Ansari A; Garcia MC; Swaim WE
    J Am Geriatr Soc; 1973 Sep; 21(9):419-24. PubMed ID: 4725407
    [No Abstract]   [Full Text] [Related]  

  • 59. Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea.
    Verner E; Forsyth C; Grigg A
    Leuk Lymphoma; 2014 May; 55(5):1139-43. PubMed ID: 23879199
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Primary thrombocythemia: a current perspective.
    Mughal TI
    Stem Cells; 1995 Jul; 13(4):355-9. PubMed ID: 7549894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.